Atazanavir: improving the HIV protease inhibitor class.
Protease inhibitors are potent agents against HIV but their use is constrained by poor pharmacokinetics, cross-resistance and metabolic toxicities. Atazanavir [Reyataz] is a new protease inhibitors with once-daily dosing and minimal lipid and glycemic effects. Resistance studies of clinical isolates reveal a mutational pattern distinctive from that of other protease inhibitors. Atazanavir selects for the I50L mutation in HIV protease that confers increased susceptibility to other protease inhibitors in vitro. Clinical trials have shown comparable efficacy to nelfinavir (Viracept) and efavirenz (Sustiva) in treatment-naive patients, and in preliminary studies, ritonavir-boosted atazanavir is effective in patients failing previous protease inhibitor-containing regimens. Reversible elevations in bilirubin occur in some patients but are not associated with hepatic injury. Atazanavir improves upon aspects of currently-available protease inhibitors and appears useful for initial and possibly subsequent HIV therapy.
Becker
Stephen
S
University of California, San Francisco and Pacific Horizon Medical Group, Inc., San Francisco, CA, USA. slbecker@mindspring.com.
D000818:Animals; D000069446:Atazanavir Sulfate; D002986:Clinical Trials as Topic / Q000639:trends; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000145:classification* / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009842:Oligopeptides / Q000494:pharmacology* / Q000627:therapeutic use*; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use*
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate